XNYSSTVN
Market cap5.61bUSD
Dec 20, Last price
20.56USD
1D
-3.66%
1Q
6.75%
IPO
5.22%
Name
Stevanato Group SpA
Chart & Performance
P/E
36.99
P/S
5.07
EPS
0.53
Div Yield, %
0.25%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
1.09b
+10.33%
Net income
146m
+1.95%
CFO
105m
+1.85%
Dividend
Jun 04, 20240.058 USD/sh
Earnings
May 22, 2025
Profile
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. operates as a subsidiary of Stevanato Holding S.R.L.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 1,085,354 10.33% | 983,700 16.57% | 843,900 27.47% | |||
Cost of revenue | 897,594 | 810,100 | 691,000 | |||
Unusual Expense (Income) | ||||||
NOPBT | 187,760 | 173,600 | 152,900 | |||
NOPBT Margin | 17.30% | 17.65% | 18.12% | |||
Operating Taxes | 43,863 | 44,600 | 31,400 | |||
Tax Rate | 23.36% | 25.69% | 20.54% | |||
NOPAT | 143,897 | 129,000 | 121,500 | |||
Net income | 145,631 1.95% | 142,849 6.35% | 134,321 71.08% | |||
Dividends | (14,294) | (13,257) | (11,647) | |||
Dividend yield | 0.20% | 0.28% | 0.20% | |||
Proceeds from repurchase of equity | 388,093 | |||||
BB yield | -6.53% | |||||
| Debt | ||||||
Debt current | 141,438 | 69,959 | 42,725 | |||
Long-term debt | 274,096 | 168,389 | 224,688 | |||
Deferred revenue | (220,666) | |||||
Other long-term liabilities | 109,392 | (116,459) | 36,300 | |||
Net debt | 342,102 | (20,126) | (172,765) | |||
| Cash flow | ||||||
Cash from operating activities | 105,210 | 103,300 | 133,300 | |||
CAPEX | (433,233) | (243,127) | (113,180) | |||
Cash from investing activities | (421,223) | (243,000) | (96,400) | |||
Cash from financing activities | 158,030 | (44,500) | 254,800 | |||
FCF | (433,152) | (181,003) | 1,198 | |||
| Balance | ||||||
Cash | 72,179 | 256,648 | 438,207 | |||
Long term investments | 1,253 | 1,826 | 1,971 | |||
Excess cash | 19,164 | 209,289 | 397,983 | |||
Stockholders' equity | 770,567 | 879,061 | 734,338 | |||
Invested Capital | 1,619,463 | 994,593 | 677,667 | |||
ROIC | 11.01% | 15.43% | 19.60% | |||
ROCE | 11.46% | 14.17% | 13.97% | |||
| EV | ||||||
Common stock shares outstanding | 264,978 | 264,699 | 264,699 | |||
Price | 27.29 51.86% | 17.97 -19.96% | 22.45 | |||
Market cap | 7,231,237 52.02% | 4,756,650 -19.96% | 5,942,503 | |||
EV | 7,573,454 | 4,736,304 | 5,769,323 | |||
EBITDA | 266,240 | 238,423 | 209,282 | |||
EV/EBITDA | 28.45 | 19.87 | 27.57 | |||
Interest | 4,227 | 29,800 | 18,800 | |||
Interest/NOPBT | 2.25% | 17.17% | 12.30% | |||